imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)

We are honoured to announce that our esteemed advisor, Prof. Dr. Petter Brodin, has launched the “imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)” study in partnership with Karolinska University Hospital and Pfizer.

This groundbreaking study aims to investigate the efficacy of orally administered nirmatrelvir/ritonavir in improving the quality of life for non-hospitalized adult participants suffering from post-acute COVID-19 syndrome (PACS). Currently, there is no curative treatment for PACS, and the focus is on symptom management and personalized rehabilitation.

Petter Brodin’s interventional, randomized, and placebo-controlled clinical intervention trial will evaluate the potential benefits of nirmatrelvir/ritonavir (Paxlovid®) compared to placebo/ritonavir. The study will enrol 400 patients with severe PACS, identified from a database of 988 patients who have received comprehensive clinical and laboratory examinations at the Karolinska University Hospital Post-COVID clinics since May 2020.

In addition to assessing the impact on patients’ quality of life, the study includes deep exploratory systems-level analyses of the immune system in PACS patients, investigating the changes induced by nirmatrelvir/ritonavir treatment. This research holds significant promise in addressing the unmet medical needs of non-hospitalized patients with post-COVID, shedding light on potential long-term solutions.

We extend our deepest gratitude to Petter Brodin for his invaluable contribution to the field of long COVID research. His dedication and expertise in the study’s design and implementation will undoubtedly advance our understanding and provide new hope for individuals suffering from this challenging condition.

Stay tuned for updates as we eagerly follow the progress of the PROLIFIC study and its potential impact on improving the lives of post-COVID patients.

Read more about it below:

https://clinicaltrials.gov/ct2/show/NCT05823896 

#PROLIFICstudy #LongCOVID #ResearchInnovation #MedicalBreakthrough #QualityofLife #ProudAdvisor